A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND ANTI-TUMOR ACTIVITY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER

Registry ID

TARA-002-101-PH2

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PROTARA THERAPEUTICS, INC

Start date

2024-06-20

Last update

2024-05-10

Conditions

• NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Related clinical trials

• A PHASE 2, MULTI-ARM, MULTI-COHORT, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRETOSTIMOGENE GRENADENOREPVEC IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
• A PHASE 2 OPEN-LABEL RANDOMIZED STUDY OF V940 IN COMBINATION WITH BCG VERSUS BCG MONOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (INTERPATH-011)
• A PHASE 3, RANDOMISED, MULTI-CENTRE, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)"
• A PHASE 1/2 OPEN-LABEL CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) IN PARTICIPANTS WITH INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
• A PHASE 3B, RANDOMISED, CONTROLLED TRIAL OF NADOFARAGENE FIRADENOVEC VS. OBSERVATION IN SUBJECTS WITH INTERMEDIATE RISK (IR) NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
• A PHASE 1/2 STUDY OF EG-70 AS AN INTRAVESICAL ADMINISTRATION TO PATIENTS WITH BCG-UNRESPONSIVE NMIBC AND HIGH-RISK NMIBC PATIENTS WHO ARE BCG NAÏVE OR RECEIVED INCOMPLETE BCG TREATMENT

View on source registry